These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19477127)

  • 1. Improving the species cross-reactivity of an antibody using computational design.
    Farady CJ; Sellers BD; Jacobson MP; Craik CS
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3744-7. PubMed ID: 19477127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies.
    Sun J; Pons J; Craik CS
    Biochemistry; 2003 Feb; 42(4):892-900. PubMed ID: 12549907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1).
    Farady CJ; Sun J; Darragh MR; Miller SM; Craik CS
    J Mol Biol; 2007 Jun; 369(4):1041-51. PubMed ID: 17475279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering of a macromolecular scaffold to develop specific protease inhibitors.
    Stoop AA; Craik CS
    Nat Biotechnol; 2003 Sep; 21(9):1063-8. PubMed ID: 12923547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
    Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
    J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bivalent inhibition of human beta-tryptase.
    Schaschke N; Matschiner G; Zettl F; Marquardt U; Bergner A; Bode W; Sommerhoff CP; Moroder L
    Chem Biol; 2001 Apr; 8(4):313-27. PubMed ID: 11325588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus.
    Frecer V; Kabelác M; De Nardi P; Pricl S; Miertus S
    J Mol Graph Model; 2004 Jan; 22(3):209-20. PubMed ID: 14629979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The structure of the pro-apoptotic protease granzyme B reveals the molecular determinants of its specificity.
    Waugh SM; Harris JL; Fletterick R; Craik CS
    Nat Struct Biol; 2000 Sep; 7(9):762-5. PubMed ID: 10966646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of sequence-reactivity space for protein-protein interactions.
    Li J; Yi Z; Laskowski MC; Laskowski M; Bailey-Kellogg C
    Proteins; 2005 Feb; 58(3):661-71. PubMed ID: 15624216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of an Fab-protease complex reveals a highly specific non-canonical mechanism of inhibition.
    Farady CJ; Egea PF; Schneider EL; Darragh MR; Craik CS
    J Mol Biol; 2008 Jul; 380(2):351-60. PubMed ID: 18514224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-function relationship of serine protease-protein inhibitor interaction.
    Otlewski J; Jaskólski M; Buczek O; Cierpicki T; Czapińska H; Krowarsch D; Smalas AO; Stachowiak D; Szpineta A; Dadlez M
    Acta Biochim Pol; 2001; 48(2):419-28. PubMed ID: 11732612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unraveling sub-site specificities of peptidic serine protease inhibitors by substitutional and structural analysis.
    Höhne W; Hilpert K
    Protein Pept Lett; 2005 Jul; 12(5):449-56. PubMed ID: 16029157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Affinity and specificity of serine endopeptidase-protein inhibitor interactions. Empirical free energy calculations based on X-ray crystallographic structures.
    Krystek S; Stouch T; Novotny J
    J Mol Biol; 1993 Dec; 234(3):661-79. PubMed ID: 8254666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two hands (or four) are better than one.
    Dunn BM; Bungert J
    Nat Biotechnol; 2003 Sep; 21(9):1019-21. PubMed ID: 12949566
    [No Abstract]   [Full Text] [Related]  

  • 15. The conformational analysis of serine protease inhibitors and its applications for drug design.
    Wibley KS; Barlow DJ
    J Enzyme Inhib; 1992; 5(4):331-8. PubMed ID: 1285254
    [No Abstract]   [Full Text] [Related]  

  • 16. Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology.
    Damalanka VC; Han Z; Karmakar P; O'Donoghue AJ; La Greca F; Kim T; Pant SM; Helander J; Klefström J; Craik CS; Janetka JW
    J Med Chem; 2019 Jan; 62(2):480-490. PubMed ID: 30571119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis of antibody-antigen interactions.
    Sundberg EJ
    Methods Mol Biol; 2009; 524():23-36. PubMed ID: 19377934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and biochemical studies of inhibitor binding to human cytomegalovirus protease.
    Khayat R; Batra R; Qian C; Halmos T; Bailey M; Tong L
    Biochemistry; 2003 Feb; 42(4):885-91. PubMed ID: 12549906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of protein-protein interactions in serine protease-inhibitor and antibody-antigen complexes: implications for the protein docking problem.
    Jackson RM
    Protein Sci; 1999 Mar; 8(3):603-13. PubMed ID: 10091663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue.
    Takeuchi T; Shuman MA; Craik CS
    Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11054-61. PubMed ID: 10500122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.